Brief: Celldex Therapeutics To Advance CIndU Into Phase 3 Development

Celldex Therapeutics

29/07/2024 21:13

July 29 (Reuters) - Celldex Therapeutics Inc  CLDX.O :
    * CELLDEX THERAPEUTICS PRESENTS POSITIVE TOPLINE RESULTS
FROM
BARZOLVOLIMAB PHASE 2 STUDY IN CHRONIC INDUCIBLE URTICARIA
    * CELLDEX THERAPEUTICS INC - TO ADVANCE CINDU INTO PHASE 3
DEVELOPMENT
    * CELLDEX THERAPEUTICS INC - BARZOLVOLIMAB SHOWS RAPID AND
DURABLE
RESPONSES
    * CELLDEX THERAPEUTICS INC: STUDY MET PRIMARY ENDPOINT

Source text for Eikon:  ID:nGNX4msN3Y 
Further company coverage:  CLDX.O 

 ((Reuters.Briefs@thomsonreuters.com;))